The 7.5% Yield That Doesn't Need a Miracle

There is a particular kind of stock that income investors dream about but rarely find. It pays a high yield. The yield is growing. The cash that funds the dividend is demonstrably real, not an accounting fiction. And almost nobody is paying attention to it.

Chesnara plc (CSN.L) is that stock.

If you read our Boredom Baron deep dive on Chesnara, you already know the business model: a disciplined consolidator of closed life insurance books across the UK, the Netherlands, and Sweden, now expanding into Luxembourg. The Baron asked the value investor's question, "is this undervalued?" Today we are asking the income investor's question, and it is a different question entirely: can I live off this cashflow for 20 years?

I am going to do something unusual with this piece. I am going to build the strongest possible bull case for Chesnara as an income holding. Then I am going to tear it apart with the strongest possible bear case, using the same data and the same sources. Then I am going to put both cases on the table, score each argument, and tell you what I actually think, including a concrete framework for anyone holding or considering this stock.

The point is not to sell you on Chesnara. It is to show you how a rigorous income investor should think about any high-yield stock.

At the current share price of approximately 302p and a total FY2025 dividend of 22.50p per share, Chesnara delivers a trailing yield of roughly 7.5%. The dividend has been increased for 21 consecutive years, including through the COVID-19 pandemic. Cash remittances from subsidiaries cover the dividend at 1.1x, and underlying Operating Capital Generation covers it at approximately 1.5x. The Solvency Coverage Ratio of 257% provides a massive buffer against regulatory intervention. The UK does not impose withholding tax on ordinary dividends, meaning European investors receive the full 7.5% gross. And the board has signaled a further 6% increase on the interim 2026 dividend.

Those are the numbers. Now let me show you what sits beneath them.

For income investors encountering Chesnara for the first time, the business model deserves a careful explanation because it is unlike anything most equity investors have encountered, and the mechanics of how it generates cash are directly relevant to dividend sustainability.

Chesnara is a consolidator of life insurance and pension books. When a large insurer decides it no longer wants to manage a portfolio of legacy policies (because the portfolio is closed to new business, the policies are complex to administer, or the capital tied up could be deployed elsewhere), Chesnara steps in and acquires that portfolio. It then manages those policies through to maturity, collecting management fees along the way and releasing the regulatory capital that was held against the liabilities as they run off.

The group today comprises four operating segments. Countrywide Assured and the newly rebranded Chesnara Life (formerly HSBC Life UK) handle the UK closed book operations. Scildon operates in the Netherlands as an open life and pensions business (formed through the merger of the closed Waard Group and the open Scildon entity, completed in 2025). And Movestic runs the Swedish life and pensions business, which is open to new business and writes pension, savings, and custodian products.

The critical insight for income investors is this: Chesnara's revenue is not driven by underwriting new insurance risk (which is cyclical and competitive). It is driven by administering existing policies (which is predictable and contractual) and releasing capital as liabilities run off (which is mathematically certain, subject only to mortality and lapse assumptions). This is a fundamentally different risk profile from a traditional insurer, and it is why the dividend has been so stable.

Here is where Baron's Cashflow earns its name, because we need to understand not just what the dividend is, but where the money actually comes from and how many layers of protection sit between you and a dividend cut. This is the section I encourage you to read slowly.

The primary measure of Chesnara's cash-generating power is Operating Capital Generation, which measures the Solvency II capital the group generates from operational activities. Think of it as the insurance equivalent of free cash flow, except it is measured under the regulatory framework rather than IFRS accounting.

In FY2025, OCG came in at £94 million, up 19% year-on-year. Now, I want to be honest about this number because management was honest about it on the earnings call. CFO Tom Howard was quite explicit that the £94 million figure was boosted by management actions (including mass-lapse reinsurance in the UK and FX hedging optimization). His guidance was that the underlying OCG, the sustainable run-rate excluding these one-off actions, is roughly 80% of the reported number. That gives us an underlying OCG of approximately £75 to 80 million.

The total dividend bill for Chesnara's roughly 231 million shares at 22.50p per share comes to approximately £52 million. Underlying OCG cover on the dividend is therefore approximately 1.5x. That is comfortable coverage by any reasonable standard.

But here is what makes me sit up. Panmure Gordon analyst Abid Hussain suggested on the earnings call that, on his numbers, dividend cover could reach approximately two times by 2028. The reason is that HSBC Life (UK), which was only completed in January 2026, will begin contributing OCG from FY2026 onwards. Management has guided that HSBC Life alone is expected to generate over £800 million in incremental lifetime cash generation, with more than £140 million of that anticipated in the first five years. The Scottish Widows Europe acquisition adds a further €250 million of lifetime cash generation, with approximately €100 million in the first five years.

The way I see it, dividend cover is not just adequate today, it is on a trajectory to become very strong over the next two to three years as the recent acquisitions begin contributing.

OCG is generated at the subsidiary level. For it to become a dividend in your pocket, it needs to flow up from the operating companies to the group holding company as cash remittances. This is not automatic; it requires regulatory approval and depends on each subsidiary maintaining adequate solvency.

In FY2025, cash remittances from subsidiaries climbed 30% to £58 million (FY2024: £45 million). Against the £52 million dividend bill, that is cash remittance cover of approximately 1.1x. Tight? On the surface, yes. But the gap between OCG (£94 million reported, £75 to 80 million underlying) and remittances (£58 million) represents capital that was generated but retained at the subsidiary level, either because it was not yet needed at group or because management chose to retain it for regulatory buffer purposes.

CFO Tom Howard confirmed on the earnings call that there is full capital fungibility from business units into the group center. This is not theoretical capital trapped behind regulatory walls. It can and does move.

Even if something goes temporarily wrong with remittances, the group holds substantial central liquidity. Post-HSBC Life completion, central liquidity stands at approximately £266 million, comprising £116 million in cash and a £150 million revolving credit facility. That is more than five years of dividend payments held in reserve at the center. The updated financial framework formalizes a target of cash cover of at least 1.0x, and Chesnara's actual delivery of 1.4x (on an OCG basis) exceeds its own floor by a substantial margin.

I know what you are thinking. A high yield with growing dividends sounds wonderful in a spreadsheet. But does it actually hold up when things go wrong?

Chesnara has increased its dividend every single year since its 2004 IPO. Twenty-one consecutive years. Management describes this record as "unrivalled in UK and European insurance," and I have spent a meaningful amount of time trying to find a counter-example. I have not found one.

The 10-year dividend CAGR through FY2024 was a steady 3.0%, broadly tracking inflation. That was the old Chesnara, the pre-acquisition-spree Chesnara. The FY2025 results marked a clear inflection point: the board recommended a final dividend of 14.80p per share, representing a 6% increase, and signaled a further 6% increase on the interim 2026 dividend before returning to annual review.

FY2019: 21.30p. FY2020: 21.94p (pandemic year, increased while peers cut). FY2021: 22.58p. FY2022: 23.28p. FY2023: 23.97p. FY2024: 21.24p (rebased after the rights issue dilution). FY2025: 22.50p (the 6% step-up on the new, enlarged share count).

That FY2024 figure deserves a careful explanation. Chesnara conducted a £140 million rights issue to fund the HSBC Life (UK) acquisition, issuing new shares at a heavily discounted price of 176p, a 40% discount to the pre-announcement share price of 293.50p. The rights issue bonus factor of 1.15x has been applied to rebase historical dividend per share metrics. Total dividend payments to shareholders actually increased. The rebased FY2025 figure of 22.50p on the enlarged share count represents a real 6% increase in income per share. The rights issue received 88% acceptance, with the rump placed at 255p, a 45% premium to the rights price, confirming the attractiveness of the terms.

What matters most for income investors is how Chesnara behaved when it was tested. During COVID-19, Phoenix Group froze its dividend. Several smaller UK life companies suspended or cut payouts entirely. Chesnara increased. That is a management team and a business model that have earned the right to be taken seriously.

For income investors, solvency is not an abstract regulatory concept. It is the distance between your dividend and a forced capital conservation measure.

Chesnara's Solvency Coverage Ratio stood at 257% at FY2025 reporting. Eligible own funds of £859 million (up 34% year-on-year) exceed the £334 million Solvency Capital Requirement by £525 million. Phoenix Group operates at roughly 172%. Just Group at approximately 179%.

I want to be intellectually honest here. The 257% is optically inflated by pre-acquisition capital raises. On a pro-forma basis including HSBC Life (UK), the ratio moderates to approximately 180%, still 20 percentage points above the top of Chesnara's stated 140% to 160% operating range. Including Scottish Widows Europe, the pro-forma ratio remains at approximately 173%, and management expects own funds to grow to approximately £1 billion on a pro-forma basis.

The bond portfolio backing non-linked liabilities is 99% investment grade (17% AAA, 22% AA, 44% A, 17% BBB). This is not a business taking credit risk to manufacture yield. Leverage has improved: the Fitch-basis leverage ratio fell to 22% (FY2024: 31%), well below the group's long-term ambition of 30% or less.

Here is where Chesnara becomes genuinely interesting for the long-duration income investor, the person asking not just "what is the yield today?" but "will this dividend still be growing in 2035?"

Closed book consolidation has a natural headwind: books run off. Without acquisitions, a closed book portfolio would shrink to zero over decades. Chesnara's answer is a three-pronged strategy, and the execution over the past twelve months has been transformational.

Acquisitions at accelerating scale. The timeline tells the story: City of Westminster Assurance for £70 million in 2007. Save & Prosper for £63.5 million in 2010. Legal & General Netherlands for £137 million in 2017. Then in rapid succession: Canada Life UK books in 2024, HSBC Life (UK) for £260 million (completed January 2026, the largest deal in Chesnara's history, adding approximately £4 billion of AUA and over 450,000 policyholders), and Scottish Widows Europe for €110 million (announced February 2026, adding €1.7 billion of AUA and 46,000 policies). The Scottish Widows deal was priced at 0.64x FY2024 own funds of €173 million, meaning Chesnara is buying £1 of regulatory capital for 64p. Combined, the two recent deals have added more than £1 billion of future lifetime cash generation.

CEO Steve Murray indicated on the FY2025 earnings call that the pipeline remains "positive" and the company has internal firepower for approximately £100 million of additional deals without external financing.

Organic new business. Movestic in Sweden reported a 62% increase in net client cash flows in its pension and savings segment. The business launched a collaboration with a new digital-only wealth builder platform and announced a new distribution agreement in Norway. Scildon's new Mortgage Lifestyle proposition is driving Dutch growth. Group New Business Contribution for FY2025 reached £12 million. New business will never be the primary driver of Chesnara's cashflow, but it provides a meaningful organic offset to natural run-off.

The European platform. The Scottish Widows deal gives Chesnara a regulated platform in Luxembourg, the premier domicile for cross-border life insurance in the EU, serving policyholders in Germany, Austria, and Italy. Four regulated jurisdictions across Europe. Total AUA now exceeds £20 billion on a pro-forma basis, up from approximately £11 billion just eighteen months ago. The company now administers approximately 1.4 million policies, achieved FTSE 250 status during 2025, and won the PLC Awards "Transaction of the Year" for the HSBC Life acquisition.

Chesnara has been executing a multi-year Transition and Transformation (T&T) program in the UK, migrating policy administration to a new operating platform managed by SS&C Technologies. Four successful migrations have been completed, and the company is leveraging AI to potentially accelerate future migration timelines. Why does this matter for income investors? Because consolidating disparate systems onto a single platform generates operating efficiencies that flow directly through to OCG. Every pound saved on administration is a pound available for dividends.

This is where Baron's Cashflow readers sit up. The United Kingdom does not impose withholding tax on ordinary dividends paid by UK companies to non-resident investors. Zero. Whether you are sitting in Germany, the Netherlands, France, Italy, or anywhere else in Europe, the 7.5% gross yield arrives as a 7.5% gross yield. No reclaim forms. No bureaucratic friction. Compare that to 12.8% French WHT on Tikehau Capital, or 35% Swiss WHT requiring years-long reclaims.

For a European income investor navigating the PRIIPs minefield, a UK-listed company paying a high, growing, covered dividend with zero withholding tax is about as structurally efficient as it gets.

Phoenix Group yields approximately 7.4 to 7.7%, broadly comparable, but the five-year dividend CAGR has been approximately 2.6%, well below Chesnara's current 6% trajectory. Phoenix's solvency ratio sits at approximately 172%, leverage and group complexity are meaningfully higher. Legal & General offers around 8% but faces structural questions about Solvency UK transition. Just Group yields barely 1.2%.

Chesnara stands out for the combination of five attributes: yield level (7.5%), yield growth trajectory (6%), dividend track record (21 unbroken years), withholding tax efficiency (0%), and balance sheet strength (180% pro-forma solvency). I struggle to find another European-listed income opportunity that ticks all five boxes simultaneously.

You buy Chesnara today at 302p. You receive 22.50p in Year 1, a 7.5% starting yield. At 4% annual dividend growth (well below the current 6%), your yield on cost reaches approximately 11.1% by Year 10 and roughly 16.4% by Year 20. At 6% growth, those figures become approximately 13.5% and 24.1% respectively. A Peel Hunt analysis highlighted that the HSBC Life acquisition underpins a 3% dividend per share growth outlook extended across a 10-year forecast horizon. Even that conservative base case implies yield-on-cost above 10% by Year 10.

That is the bull case. Now let me destroy it.

Every number I just showed you has an uncomfortable mirror image. A rigorous income investor must hold both in tension, and I refuse to pretend the bear case does not exist. What follows is the strongest short-seller's argument I can construct against Chesnara, using the same data and the same sources. I am going to give the bear its full hearing, because if this piece is going to be worth anything, it has to survive the hardest questions.

Let's start with the number that Chesnara's management would very much prefer you did not focus on.

The FY2025 IFRS profit before tax was £19 million. Not £94 million. Not £56 million. Nineteen million pounds, on a company with a £700 million market capitalization. That is a price-to-earnings ratio that would make a speculative biotech blush. And the first half of 2025 was worse: Chesnara reported an outright IFRS pre-tax loss of £5 million.

But wait, management will tell you. IFRS is not the right framework. You should look at Operating Capital Generation. You should look at Adjusted Operating Profit. You should look at the metrics in our updated financial framework, which we conveniently introduced for the first time in the FY2025 results, replacing the old metrics.

Let me translate: Chesnara changed its performance measurement framework in the same year it posted record "profits" under the new metrics. The Adjusted Operating Profit of £56 million is derived by taking the £19 million IFRS figure and adding back £40 million of integration and restructuring costs and £11 million of financing charges. In other words, management's preferred metric excludes the costs of running the acquisition machine that is the entire basis of the investment thesis.

And here is the uncomfortable question: if IFRS is irrelevant noise, why has the IFRS Capital Base only grown to £694 million because of £245 million of capital issuances, not because of retained earnings? The FY2025 investor presentation shows this clearly on the IFRS Capital Base waterfall: the £280 million capital raises dwarf the £56 million Adjusted Operating Profit contribution, and the non-operating adjustments, tax, and CSM movements consume most of the operating profit before it reaches the equity line. Strip out the equity raise and bond issue, and the IFRS equity base barely moved. The company is not compounding its equity through profits. It is compounding its equity through dilution.

This is the arithmetic that keeps me honest, and it comes directly from Chesnara's own investor presentation, page 12, the Central Liquidity waterfall.

Total annual outflows from the group center: £42 million (dividends) plus £10 million (debt servicing costs) plus £32 million (other center costs) equals £84 million per year before the Chesnara Life consideration. Add the RT1 coupon at 8.5% on £150 million (approximately £12.75 million, which is embedded within the debt servicing and center cost lines going forward), and the fully-loaded annual center requirement approaches £97 million. Cash remittances from subsidiaries were £58 million.

That is a £39 million annual shortfall between what the subsidiaries actually remit and what the group center needs. The gap was filled in FY2025 by the proceeds from £280 million of combined capital raises. The £266 million of post-acquisition central liquidity that management highlights exists because shareholders and bondholders just injected £280 million. It is not a sign of operational cash generation. It is a sign of successful capital market fundraising.

The bull will argue that the £32 million of center costs includes one-off integration spending. That is probably true. But even if steady-state center costs are £20 million lower, the shortfall narrows rather than disappears, and the question becomes whether HSBC Life remittances will bridge the remaining gap quickly enough.

Twenty-one consecutive years of dividend increases. It sounds magnificent. But let me be precise about what actually happened to shareholders in FY2024 and FY2025.

In FY2023, the dividend per share was 23.97p. In FY2024, after the rights issue, the reported dividend per share was 21.24p. That is a decline of 11.4% in the number printed on your brokerage statement. Management will show you a different table, applying a rights issue bonus factor of 1.15x to rebase historical dividends so that the FY2025 figure of 22.50p appears to be a 6% increase. The arithmetic is technically correct, and the methodology is standard practice for rights issues.

But the practical reality for any shareholder who did not participate in the rights issue (and 12% did not) is that their dividend per share fell and their ownership stake was diluted by approximately 34.5%. The rights issue was priced at 176p, a 40% discount to the pre-announcement share price of 293.50p. This is not a small, routine capital raise. This is a deeply discounted, heavily dilutive equity raise that asked shareholders to put up fresh money equivalent to more than a third of their existing holdings, at a price nearly half the prevailing market value, just to maintain their position. And it was done to fund an acquisition that is essential to prevent the underlying business from shrinking.

Here is the structural problem that no amount of alternative performance measures can obscure: Chesnara is a melting ice cube.

Closed life insurance books run off. Every year, policies mature, lapse, or end because the policyholder dies. Assets under administration decline. Fee income declines. Capital release declines. Without acquisitions, Chesnara is a business in permanent, mathematically certain decline. A typical closed book runs off at perhaps 5 to 8% per year depending on the age profile of the policies.

This means Chesnara must acquire new books at a sufficient pace to offset the natural erosion, just to keep the asset base flat. To actually grow, it must acquire at an even faster pace. And to grow while simultaneously servicing an 8.5% coupon on £150 million of RT1 debt, paying £42 million in dividends, and absorbing £32 million of other group center costs, it must acquire at a pace that is genuinely extraordinary for a company of this size.

The deals are also getting larger, which means the stakes of a single integration failure are rising. HSBC Life alone is larger than every previous Chesnara acquisition combined. If systems migration stumbles, if unexpected liabilities emerge, if the Part VII transfer (expected to complete in 2027) encounters regulatory delays, the cashflow that the bull case depends on will arrive later and smaller than projected.

In August 2025, Chesnara issued a £150 million Restricted Tier 1 bond at 8.5%. This is the most expensive form of insurance company debt, sitting below Tier 2 in the capital structure, with equity-like loss absorption features. The 8.5% coupon reflects lender assessment of the credit risk of lending to a sub-£1 billion insurance consolidator with an acquisition-dependent business model.

The annual servicing cost of approximately £12.75 million represents roughly 16% of underlying OCG (using the CFO's own guidance of 80% of reported OCG, approximately £75 to 80 million). Combined with the existing Tier 2 notes, total debt servicing reaches approximately £22.75 million per year. That is more than the IFRS pre-tax profit of £19 million. The company is, on an IFRS basis, earning less than its interest bill. If the acquisition pipeline stalls, if OCG disappoints, that 8.5% coupon does not adjust downward. It is a one-way ratchet against shareholders.

The headline solvency ratio of 257% is the number bulls point to as evidence of fortress-like balance sheet strength. It is also deeply misleading.

On a pro-forma basis including HSBC Life (UK), the ratio drops to approximately 180%. Include Scottish Widows Europe, and it falls further to approximately 173%. That is a decline of 84 percentage points from the headline number once you account for deals management has already committed to. And the 257% was created primarily by the capital raises: Chesnara itself acknowledges the solvency increase was driven "primarily by higher Own Funds from the impact of the Group's equity and debt issuances".

The sensitivity chart from the FY2025 investor presentation makes the fragility more concrete. A 25% equity fall would cost £50 million of surplus and 24 percentage points of solvency ratio. A 50 basis point credit spread widening costs £15 million and 4 percentage points. A 1% interest rate fall costs £7 million and 5 percentage points. A 10% mass lapse event costs £12 million. And a 10% expense rise (not implausible if integration costs overrun) costs £36 million and 13 percentage points. On the 173% pro-forma base, a severe but plausible combined stress scenario (equity correction plus credit spread widening plus expense overrun) could bring solvency uncomfortably close to the 140 to 160% operating range. The buffer is real, but it is not infinite.

Chesnara is covered by four analysts. Four. Morningstar does not formally cover it, instead relying on a quantitative algorithm that statistically matches it to peer companies. No hedge funds report significant positions, according to TipRanks. The average target price of 342p is based on the same alternative performance measures that management has asked everyone to use.

This is not the profile of a well-scrutinized company where information asymmetries have been arbitraged away. This is the profile of a company that exists in an attention desert, where management's narrative goes largely unchallenged. The four analysts who cover it are the same analysts who attended the results presentation, asked polite questions about dividend cover, and published "Buy" recommendations. When nobody is watching, companies tell the story they want to tell.

For the income investor, the attention desert cuts both ways. It is the reason the stock is cheap (the bull's opportunity). It is also the reason that problems, if they emerge, will be discovered late and priced violently (the bear's nightmare).

This is the risk that nobody at Chesnara wants to discuss in concrete terms, because doing so would undermine the entire economic model.

The FCA's Consumer Duty requires firms to deliver "good outcomes" for customers. For a closed book consolidator, this creates an inherent tension: Chesnara earns management fees on legacy policies that are, by definition, no longer receiving active product development, distribution support, or competitive market pricing. The policyholders are captive. They cannot easily switch. The fees they pay fund Chesnara's dividends.

The political direction of travel in UK financial regulation is toward lower fees, greater transparency, and more active scrutiny of "zombie fund" charges. If the FCA decides that legacy policy management charges are excessive relative to the service being provided, the entire unit economics of closed book consolidation change. Every basis point of fee compression flows directly through to reduced OCG, reduced cash remittances, and eventually, reduced dividends. Chesnara's predominantly unit-linked model provides partial mitigation (fees are contractual rather than discretionary), and the company's investment in the T&T platform and AI-assisted migration demonstrates genuine commitment to improving customer outcomes. But "contractual" does not mean "immune to regulatory intervention," and the post-Woodford, post-LDI-crisis political environment gives the regulator both the mandate and the incentive to act.

The most revealing moment in the FY2025 earnings call came when CFO Tom Howard addressed the OCG figure. He was, in his own words, "quite careful to say that we felt that the 2025 OCG results was very strong, which is my way of encouraging you not to put a 19% CAGR on the OCG from this point forward". He then specified that the underlying OCG (excluding management actions like mass-lapse reinsurance) is roughly 80% of reported. That takes the sustainable OCG from £94 million down to roughly £75 million.

And yet the headline in every press release, in every analyst note, in every investor presentation is "Operating Capital Generation up 19% to £94 million." When the CFO himself tells you the headline number is not sustainable, you should listen.

Let me assemble the uncomfortable arithmetic in one place. IFRS profit before tax: £19 million. Annual debt servicing (Tier 2 plus RT1): approximately £22.75 million. Annual dividend cost: approximately £42 million. Annual other group center costs: approximately £32 million. Total annual cash requirement at group center: approximately £97 million. Cash remittances from subsidiaries: £58 million. Annual shortfall: approximately £39 million. Headline solvency ratio: 257%. Pro-forma solvency ratio (post both deals): 173%. Shareholders diluted by rights issue: 34.5%. Analyst coverage: 4 brokers. Morningstar formal coverage: none. The company earns less in IFRS profit than it pays in interest. It remits less from subsidiaries than it needs at the center. And it requires continuous acquisitions just to prevent the underlying business from shrinking to zero.

I have now given you the strongest bull case and the strongest bear case I can construct, using the same data. Both are intellectually honest. Both identify real dynamics. Here is how I score each contested point.

The bear is right that the timing of the framework change is optically terrible. The bull is right that IFRS 17 genuinely is a poor fit for closed book insurance economics and that peers use similar adjusted metrics.

Resolution: Track both frameworks. Insist that IFRS performance improves over time. The test: If FY2026 IFRS profit before tax does not reach at least £30 to 40 million now that HSBC Life is contributing for the full year, the bear's "accounting illusion" thesis gains real credibility. If it does improve, the bull's "transition noise" argument holds.

The bear's £39 million shortfall arithmetic is slightly misleading because the £32 million center cost run-rate contains integration spending that is, by definition, temporary. The steady-state center cost base is probably closer to £20 to 22 million, which narrows the shortfall considerably. But the bull cannot assume HSBC Life remittances will flow immediately at scale.

The test: Track FY2026 cash remittances as the single most important number. If remittances rise toward £70 to 80 million, the shortfall thesis collapses. If they stay flat, the bear has a serious structural point.

The bull is correct on the mechanics (participating shareholders maintained their stake; the rump placement at a 45% premium confirmed the terms were attractive). The bear is correct on the optics (dividend per share fell, 12% of shareholders did not participate, the "21 consecutive increases" requires an asterisk).

The honest framing: If you are buying today, the dilution is irrelevant. You are buying the post-dilution share count at today's price, and the forward yield of 7.5% is the relevant number.

This is where the bull wins decisively, but with an important caveat. The bear frames acquisition dependence as a weakness when it is actually the entire investment thesis. Chesnara is an acquisition machine that happens to operate in closed books. Asking "what happens if they stop acquiring?" is like asking "what happens to Berkshire Hathaway if it stops allocating capital?" Technically valid, practically irrelevant.

The caveat: Competition is intensifying and pricing is tightening. The test: Track the acquisition multiple on each deal. Below 0.65x own funds: discipline holds. Above 0.70x: the bear's pricing pressure thesis gains traction.

The bull wins this round. Even at the fully pro-forma 173%, Chesnara is above Phoenix Group's 172%, above the operating range, and the 99% investment-grade bond portfolio is not taking material credit risk.

The bear has a legitimate point about expense. But the relevant comparison is to OCG (£12.75 million against £75 to 80 million is manageable), not to distorted IFRS profit. The test: If Chesnara refinances the RT1 at a lower coupon, the burden declines materially.

Chesnara is a long-duration income holding. The thesis requires patience for acquisitions to contribute, for integration costs to roll off, for IFRS profitability to normalize. If your horizon is less than three years, the execution risk is too high. You can get 7% from a fixed-income instrument without integration risk. If your horizon is five years or more, the compounding dynamics become genuinely attractive.

This is a FTSE 250 company with four analysts, an acquisition-dependent model, and IFRS profit that barely covers the interest bill. This is not a 10% core holding. It is a 2 to 4% satellite position, where the 7.5% yield provides meaningful income contribution but a permanent impairment would not be catastrophic.

Green (hold or add): FY2026 cash remittances exceed £70 million. IFRS profit before tax exceeds £30 million. Pro-forma solvency ratio stabilizes above 170%. Next acquisition priced below 0.65x own funds. Dividend increased as guided.

Amber (hold, do not add): Cash remittances flat at £55 to 65 million. IFRS profit below £25 million. Solvency ratio drifts toward 160%. Acquisition pricing creeps above 0.70x. Integration costs persist at elevated levels.

Red (reduce or exit): Cash remittances decline below £50 million. IFRS loss in a full financial year. Solvency ratio touches or breaches the 140 to 160% operating range. No acquisition completed for 18+ months. Dividend frozen or cut. FCA formal action on legacy fund fees.

For Baron's Cashflow readers specifically, the zero UK withholding tax transcends the bull-bear debate entirely. If you hold Chesnara in a tax-advantaged wrapper, the 7.5% gross yield is also the net yield. No other major European market offers this for non-resident investors.

I have given you the most thorough income analysis I have ever published, and I did it on a company most investors have never heard of. Let me tell you why.

Chesnara is, in miniature, every question an income investor must answer. Is a high yield a reward or a warning? Is dividend growth real if it requires rebasing? Is an "alternative performance measure" informative or obfuscatory? Is acquisition dependence a strategy or a vulnerability? Is low analyst coverage an opportunity or a red flag?

The answer, frustratingly, is "it depends." It depends on your time horizon, your risk tolerance, your portfolio construction, and your conviction in management. The bear and the bull are both right, about different things, on different time frames.

My own assessment leans bullish, but with open eyes. The central cost shortfall is a legitimate near-term concern that should resolve as HSBC Life contributes. The IFRS disconnect is ugly but explicable under IFRS 17 transition dynamics. The acquisition treadmill is real but well-managed, and the four-jurisdiction platform is a genuine competitive advantage that did not exist eighteen months ago. The solvency position is strong even on a fully pro-forma basis. And the zero-WHT structure is a meaningful, underappreciated edge for European income portfolios.

The position I would take: a 2 to 3% portfolio allocation, initiated at current prices, with a commitment to review the thesis at every results period using the green/amber/red framework above. Add on any pullback below 280p. Reduce if the amber triggers accumulate. Exit if any red trigger fires.

The 7.5% yield, if it compounds at even 4% per year over a decade, delivers a yield-on-cost above 11%. If management delivers on the 6% growth trajectory, it reaches 13.5%. Either outcome justifies the position for a patient income investor who understands the risks, monitors the triggers, and refuses to fall in love with the narrative while ignoring the numbers.

Both the bear's numbers and the bull's numbers are real. The question is which set of numbers matters more over your investment horizon. I believe the bull's numbers win over five-plus years. But I have been wrong before, and so I size accordingly.

The FY2025 total shareholder return of 43% (yes, 43%, from a "boring" insurance consolidator) suggests the market is slowly waking up to the quality of the business. Whether that makes today a good entry or a missed opportunity is the judgment call I cannot make for you.

Music to my ears, with a careful ear on the bass notes.

Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice. Always conduct your own due diligence before making investment decisions.

Sincerely,

The Boredom Baron